The short answer
Loren Pickart isolated GHK from the albumin fraction of human plasma in 1973, while investigating why plasma from younger donors caused liver tissue from older donors to synthesise proteins in a pattern more typical of younger tissue. The active component proved to be a tripeptide.
Key facts
- Year
- 1973
- Investigator
- Loren Pickart
- Source
- Human plasma, albumin fraction
- Original question
- Young plasma altering older liver tissue
- Early working name
- Liver cell growth factor
- Also indexed as
- Prezatide
The observation that started it
The experiment was not looking for a peptide. Plasma from young donors was added to liver tissue from older donors, and the older tissue began producing proteins in a pattern more characteristic of younger tissue. Something in young plasma was doing it, and the work that followed was an attempt to find out what.
Why albumin
The activity tracked to the albumin fraction during separation. That is a meaningful detail rather than a procedural one: albumin is the major copper-transport protein in plasma and carries its own amino-terminal copper-binding site of the same class as GHK's. Finding a copper-binding tripeptide in the albumin fraction is consistent rather than coincidental.
Research material referenced
GHK-Cu 100mg, third-party HPLC tested
The early names
The peptide was described as liver cell growth factor for a period, reflecting the assay it was found in rather than any established function. It is also indexed under the name prezatide. Both names appear in older literature and searching for them surfaces records that a search for GHK misses.
What the original work did and did not establish
It established that a specific tripeptide, isolable from human plasma, altered protein synthesis in a tissue model. It did not establish a receptor, a physiological pathway, or an effect in an organism. Fifty years of subsequent work has substantially expanded the descriptive literature; the mechanistic picture remains built largely on copper delivery rather than on a defined signalling pathway.
Why it stayed interesting
Two features. It is endogenous, present in human plasma, unlike compounds whose endogenous status is asserted rather than demonstrated. And its concentration is reported to decline with age, which gives the observation a natural narrative. Both are real; neither establishes that administering it does anything.
Frequently asked questions
What was Pickart originally studying?
Why plasma from young donors changed protein synthesis in liver tissue from older donors. GHK was the fraction responsible.
Why was it called liver cell growth factor?
It reflected the assay in which the activity was found, not an established function. The name did not survive.
Is GHK endogenous?
Yes. It was isolated from human plasma, which distinguishes it from compounds whose endogenous status remains unconfirmed.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedPickart L, The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008 (PMID 18644225)pubmed.ncbi.nlm.nih.gov
- PubMedPickart L & Margolina A. Biomed Res Int 2015 (PMID 26236730)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Glycyl-L-histidyl-L-lysine (CID 73587)pubchem.ncbi.nlm.nih.gov
- PubMedPickart L et al., The Effect of the Human Peptide GHK on Gene Expression. Brain Sci 2017 (PMID 28212278)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · GHK-Cu copper complex (CID 71587328)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More GHK-Cu (Copper Peptide) articles
- The 4,000 Genes Claim, ExaminedPickart and Margolina reported GHK modulating over 4,000 human genes using the Broad Institute Connectivity Map. What that measures, and what it does not.
- GHK-Cu Mechanism: What Is Actually ProposedThe dominant proposal is copper delivery to enzymes requiring it as a cofactor. What that explains, what it does not, and why no receptor is established.
- GHK-Cu and Collagen Synthesis ResearchLysyl oxidase requires copper to cross-link collagen. That enzyme dependency is the clearest mechanistic route from GHK-Cu to matrix effects in the literature.
- GHK-Cu and Matrikine SignallingMatrikines are peptide fragments released from matrix proteins that signal back to cells. Whether GHK qualifies is a proposed framing rather than a settled one.
- The Age-Related Decline in GHKPlasma GHK is reported to fall substantially with age. It is a correlation from observational measurement, and restoring a level is a separate claim entirely.